Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SBFM
SBFM logo

SBFM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.200
Open
1.180
VWAP
1.16
Vol
67.87K
Mkt Cap
5.64M
Low
1.140
Amount
78.96K
EV/EBITDA(TTM)
--
Total Shares
4.91M
EV
-3.46M
EV/OCF(TTM)
--
P/S(TTM)
0.11
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Show More

Events Timeline

(ET)
2025-10-28
07:48:02
Nora Pharma, a subsidiary of Sunshine Biopharma, gets Health Canada approval for domperidone.
select
2025-10-20 (ET)
2025-10-20
07:47:05
Sunshine Biopharma Reveals Launch of Doxycycline for Sale in Canada
select
2025-10-16 (ET)
2025-10-16
07:49:20
Nora Pharma, a subsidiary of Sunshine Biopharma, introduces pravastatin.
select
2025-10-14 (ET)
2025-10-14
07:16:32
Sunshine Biopharma invests $5 million in Bitcoin.
select
2025-10-09 (ET)
2025-10-09
08:22:28
Sunshine Biopharma and the University of Arizona Collaborate on Development of Protease Inhibitors
select
2025-07-02 (ET)
2025-07-02
08:22:07
Sunshine Biopharma's Nora Pharma launches NIOPEG
select
2025-06-11 (ET)
2025-06-11
08:39:01
Sunshine Biopharma launches generic gabapentin for neuropathic pain
select
2025-05-06 (ET)
2025-05-06
08:45:12
Sunshine Biopharma launches generic Lurasidone for schizophrenia
select
2025-04-21 (ET)
2025-04-21
08:38:56
Sunshine Biopharma launches Everolimus in Canada
select
2025-04-02 (ET)
2025-04-02
08:14:56
Sunshine Biopharma announces results from studies on K1.1-mRNA-LNP product
select

News

Benzinga
4.0
2025-10-08Benzinga
Aegis Capital Affirms Buy Rating for Sunshine Biopharma, Keeps $7 Price Target Intact
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights from Benzinga reporters.
TipRanks
2.0
2025-04-03TipRanks
3 Penny Stocks to Watch Now, 4/3/25
  • Penny Stocks to Watch: Sportsman’s Warehouse, Sunshine Biopharma, and ConnectM Technology Solutions are highlighted as top penny stocks on April 3, 2025, based on their high Dollar Volume and significant stock price movements following positive company news.

  • Company Highlights: Sportsman’s Warehouse saw a nearly 98% increase in stock price after strong Q4 results; Sunshine Biopharma reported a 45% revenue increase and positive study results; ConnectM Technology's shares surged due to a buyout proposal amid delisting concerns.

Benzinga
9.0
2025-04-02Benzinga
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
  • Stock Performance: Sunshine Biopharma Inc. (SBFM) saw a significant increase in stock price, rising 69.2% to $3.52, with trading volume reaching 19.07 million shares on Wednesday, compared to an average of 88.16K.

  • Research Advancements: The company announced successful studies on its K1.1 mRNA Lipid Nanoparticle product for treating human hepatocellular carcinoma, demonstrating effective tumor growth reduction and promising results for both full-length and truncated mRNA versions in mouse models.

Benzinga
4.5
2025-04-02Benzinga
US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia
  • Market Overview: U.S. stock futures fell following a mixed trading session, with major indices down in premarket as traders await President Trump's announcement on potential tariffs that could impact a significant portion of imports.

  • Economic Insights: Analysts express concerns over market uncertainty and the potential for increased volatility due to tariff implications, while also noting significant losses in major indices for March and the first quarter of the year.

Benzinga
9.5
2025-04-02Benzinga
Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket
  • Sportsman's Warehouse Earnings Report: Sportsman's Warehouse Holdings, Inc. shares surged 38.8% in pre-market trading after reporting fourth-quarter revenue of $340.4 million, exceeding analyst expectations, and adjusted earnings of four cents per share, beating estimates for a loss.

  • Market Movements: Several stocks experienced significant changes in pre-market trading, with Digital Ally, Inc. gaining 159.6%, while Jayud Global Logistics Limited saw a drastic decline of 78.3%.

SeekingAlpha
9.5
2025-04-02SeekingAlpha
Sunshine Biopharma reports FY results
  • Financial Performance: Sunshine Biopharma reported a fiscal year net loss of $5.13 million, despite achieving a revenue increase of 44.8% year-over-year, totaling $34.9 million.

  • Market Insights: The company is listed on NASDAQ under the ticker SBFM and has received a Quant Rating from Seeking Alpha, along with historical earnings data available for analysis.

Valuation Metrics

The current forward P/E ratio for Sunshine Biopharma Inc (SBFM.O) is -2.60, compared to its 5-year average forward P/E of -1.66. For a more detailed relative valuation and DCF analysis to assess Sunshine Biopharma Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.66
Current PE
-2.60
Overvalued PE
0.68
Undervalued PE
-3.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.15
Current PS
0.13
Overvalued PS
0.38
Undervalued PS
-0.08

Financials

AI Analysis
Annual
Quarterly

Whales Holding SBFM

L
L1 Capital Pty. Limited
Holding
SBFM
+19.59%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Sunshine Biopharma Inc (SBFM) stock price today?

The current price of SBFM is 1.15 USD — it has decreased -3.36

What is Sunshine Biopharma Inc (SBFM)'s business?

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

What is the price predicton of SBFM Stock?

Wall Street analysts forecast SBFM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBFM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sunshine Biopharma Inc (SBFM)'s revenue for the last quarter?

Sunshine Biopharma Inc revenue for the last quarter amounts to 9.42M USD, increased 11.64

What is Sunshine Biopharma Inc (SBFM)'s earnings per share (EPS) for the last quarter?

Sunshine Biopharma Inc. EPS for the last quarter amounts to -0.19 USD, decreased -79.79

How many employees does Sunshine Biopharma Inc (SBFM). have?

Sunshine Biopharma Inc (SBFM) has 52 emplpoyees as of March 12 2026.

What is Sunshine Biopharma Inc (SBFM) market cap?

Today SBFM has the market capitalization of 5.64M USD.